The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

The extended review for Elinzanetant is supported by data from the Phase III OASIS 1, 2, and 3 trials, which supported the ...

While MSN reports that Sarepta’s stock price began to rise on Monday on the heels of the announcement, 5 the company is still facing challenges. Shipments of the gene therapy for non-ambulatory ...

PE: Where has AI been successfully implemented already? Li: We’re current working with three of the top 10 pharmaceutical ...

Hengrui Pharma partners with GSK to develop 12 innovative medicines, enhancing COPD treatment and expanding global growth ...

John Showalter, MD, MSIS, chief operating officer at Linus Health, added, “We've built our platform to be embedded ...

AI influencers represent the cutting edge of digital storytelling. But when applied to pharmaceutical marketing, innovation must be balanced with integrity.

Boehringer Ingelheim partners with Re-Vana Therapeutics to innovate long-acting eye disease treatments, enhancing patient care and compliance.

Despite surging GenAI adoption in pharma and the FDA’s recent embrace of the technology, a trust gap remains with GenAI implementations. The story describes four essentials that improve trust in GenAI ...

Under terms of the deal, Bavarian Nordic shareholders will receive an all-cash offer at a premium, with plans to delist the ...

The regulatory actions were based on results from the Phase III MATTERHORN trial (NCT04592913), which showed that a ...